Evogene Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;'>EVG</div>
EVGN -- USA Stock  

USD 6.08  0.13  2.18%

Despite quite unfluctuating technical and fundamental indicators, Evogene disclosed solid returns over the last few months and may actually be approaching a breakup point. The company current chance of financial distress is under 1 percent. Will institutional investors continue to be optimistic, or should we expect a sell-off?
Published over three months ago
View all stories for Evogene | View All Stories
Does Evogene (NASDAQ:EVGN) have persistent technical and fundamental indicators based on the latest rise?
Evogene holds a performance score of 20 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.8391, which means possible diversification benefits within a given portfolio. Let's try to break down what Evogene's beta means in this case. As returns on the market increase, returns on owning Evogene are expected to decrease at a much lower rate. During the bear market, Evogene is likely to outperform the market. Although it is essential to pay attention to Evogene historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards predicting future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if Evogene expected return of 2.52 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Evogene semi variance, and the relationship between the treynor ratio and daily balance of power to analyze future returns on Evogene.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Evogene income statement, its balance sheet, and the statement of cash flows. Potential Evogene investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Evogene investors may use each financial statement separately, they are all related. The changes in Evogene's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Evogene's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Evogene fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Evogene performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Evogene shares is the value that is considered the true value of the share. If the intrinsic value Evogene is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Evogene. Please read more on our fundamental analysis page.

Are Evogene Earnings Expected to grow?

The future earnings power of Evogene involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Evogene factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Evogene stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Evogene expected earnings.

How Evogene utilizes its cash?

To perform a cash flow analysis of Evogene, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Evogene is receiving and how much cash it distributes out in a given period. The Evogene cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Evogene Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (16.32 Million)

Evogene Gross Profit

Evogene Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Evogene previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Evogene Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

What is driving Evogene Investor Appetite?

Evogene reported the previous year's revenue of 586 K. Net Loss for the year was (20.78 M) with profit before overhead, payroll, taxes, and interest of 419 K.
 2017 2018 2019 2020 (projected)
Book Value per Share2.71.941.952.39
Asset Turnover0.0390.0260.0120.0123

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evogene has an asset utilization ratio of 0.52 percent. This suggests that the company is making $0.005204 for each dollar of assets. An increasing asset utilization means that Evogene is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
60.3 M
Assets Non Current
24.1 M
21.2 M
Current Assets60.28 Million57.1
Assets Non Current24.1 Million22.83
Goodwill21.19 Million20.07

Over 3 percent rise for Evogene. What does it mean for institutional investors?

Total risk alpha is down to 1.65. It may entail a possible volatility slide. Evogene is displaying above-average volatility over the selected time horizon. Investors should scrutinize Evogene independently to ensure intended market timing strategies are aligned with expectations about Evogene volatility.

Whereas some other companies under the biotechnology industry are still a bit expensive, Evogene may offer a potential longer-term growth to institutional investors. The inconsistency in the assessment between current Evogene valuation and our trade advice on Evogene is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Evogene.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Evogene. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com